Overview
Michelle joined the NIHR Exeter Clinical Research Facility (CRF) and UEMS as Research Project Manager in 2010. Her role entails working up and managing research studies (often multi-centred) for academics using the CRF or CTU, from concept to full study and beyond.
Michelle currently manages several diabetes research studies, including the DUK-funded EXE-T1D study of extremely early-onset Type 1 diabetes and the EU-funded DIRECT Consortium Type 2 Diabetes Progression study.
She also manages two ‘recruit by genotype’ studies exploring the role of genetic variation on insulin secretion and sensitivity defects (DIVA), and improving our understanding of how fat in the body works (fATDIVA), with the aim of identifying why some people develop Type 2 diabetes. Previous studies include: the UNITED Project (funded by Wellcome Trust/Dept of Health), a 3 year multi-centre study that tested a complete care pathway for the appropriate diagnosis and treatment of young-onset diabetes; and the MRC-ABPI ProMASTER study looking at drug response to specific second- and third-line classes of treatment for Type 2 diabetes. These studies successfully met their objectives and will lead to several important publications and further research.
Prior to joining the UEMS, Michelle worked as a primary school teacher with a particular interest in Science, Design & Technology, English and PE. Her career began in medical publishing in London before moving to the west country.
If contacting with sensitive or personal information, please use: michelle.hudson4@nhs.net
Qualifications
- BSc (Southampton)
- 2003 Qualified Teacher Status
Career
2010 – Present: Research Project Manager, University of Exeter College of Medicine and Health, and NIHR Exeter Clinical Research Facility
Previous:
Class Teacher (with additional Teaching and Learning Responsibilities)
Partner and founder of Bougham Trout Farm
Health Sciences Promotions Manager - W.B. Saunders and Baillière Tindall (medical and nursing publishers)
Research
Research interests
Michelle currently manages research in the areas of diabetes and genetic variants that may influence insulin production and processing, and fat storage. In the future, her role can be applied across other areas of medical and experimental research.
Research projects
- EXE-T1D (EXtremely Early-onset Type 1 Diabetes) - DUK funded (CI: Dr Richard Oram)
- DIVA (DIabetes VAriants) – MRC funded (CI: Prof T Frayling)
- fATDIVA (for Adipose Tissue DIabetes VAriants – ERC funded (CI: Prof T Frayling)
- DIRECT T2D Progression – EU DIRECT Consortium (CI: Prof M Walker)
- ProMASTER – MRC funded (CI: Prof A Hattersley)
- UNITED – Wellcome Trust/DoH funded (CI: Prof A Hattersley)
Research networks
UK Trial Managers Network (UKTMN)
Exeter Clinical Trials Support Network (ECTSN)
Publications
Key publications | Publications by category | Publications by year
Publications by category
Journal articles
Koivula RW, Forgie IM, Kurbasic A, Viñuela A, Heggie A, Giordano GN, Hansen TH, Hudson M, Koopman ADM, Rutters F, et al (2019). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.
Diabetologia,
62(9), 1601-1615.
Abstract:
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.
AIMS/HYPOTHESIS: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up). METHODS: from a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe. RESULTS: Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l. CONCLUSIONS/INTERPRETATION: the IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.
Abstract.
Author URL.
Shields B, Shepherd M, Hudson M, McDonald T, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson E, et al (2017). Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients.
Diabetes Care Full text.
Publications by year
2019
Koivula RW, Forgie IM, Kurbasic A, Viñuela A, Heggie A, Giordano GN, Hansen TH, Hudson M, Koopman ADM, Rutters F, et al (2019). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.
Diabetologia,
62(9), 1601-1615.
Abstract:
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.
AIMS/HYPOTHESIS: Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up). METHODS: from a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe. RESULTS: Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l. CONCLUSIONS/INTERPRETATION: the IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.
Abstract.
Author URL.
2017
Shields B, Shepherd M, Hudson M, McDonald T, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson E, et al (2017). Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients.
Diabetes Care Full text.
Michelle_Hudson Details from cache as at 2021-01-24 02:48:41
Refresh publications
Teaching
A session for BSc Medical Sciences Optional Module (Year 3)
Managing Clinical Trials: Putting Science into Practice (CSC4004)